12:00 AM
Jun 25, 2012
 |  BioCentury  |  Strategy

Fragile X connection

Why Seaside, Roche partnered on mGluR5 and GABA B programs for fragile X

Last week's deal between Seaside Therapeutics Inc. and Roche has a slew of moving parts, with a different driver for each party. The key for the biotech was granting Roche an option to its lead fragile X syndrome program, which could allow Seaside to leverage the pharma's commercial muscle. Meanwhile, the pharma gains freedom to operate in the mGluR5 antagonist space, both in terms of IP and running clinical trials.

Fragile X syndrome is the most common known genetic form of autism. It is characterized by impaired neural and cognitive development caused by transcriptional silencing of a gene encoding the fragile X mental retardation protein (FMRP) (see BioCentury, Nov. 2, 2009).

There are no drugs for fragile X, which is an Orphan indication. It is more prevalent in males, where it is thought to occur in one in 5,000 births. Preclinical evidence suggests modulating targets like mGluR5 and GABA B could have disease modifying potential.

Seaside has been pursuing both targets. Under last week's deal, Roche will receive an option to commercialize Seaside's...

Read the full 858 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >